EXPLANATORY STATEMENT

NATIONAL HEALTH ACT 1953

*NATIONAL HEALTH (LISTING OF PHARMACEUTICAL BENEFITS)*  
*AMENDMENT (AUGUST UPDATE) INSTRUMENT* *2025*

PB 84 of 2025

Purpose

The purpose of this legislative instrument, made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the *National Health Act 1953* (the Act), is to amend the *National Health (Listing of Pharmaceutical Benefits) Instrument 2024* (PB 26 of 2024) to make changes to the pharmaceutical benefits listed for the purposes of the Pharmaceutical Benefits Scheme (PBS), and related matters.

The *National Health (Listing of Pharmaceutical Benefits) Instrument 2024* determines the pharmaceutical benefits that are on the Schedule of Pharmaceutical Benefits (the PBS Schedule) through declarations of drugs and medicinal preparations, and for ready-prepared benefits: determinations of forms, manners of administration and brands. It also provides for related matters (equivalent brands, responsible persons, prescribing circumstances, maximum quantities, number of repeats, determined quantity and pack quantity, section 100 only status and prescriber bag only status).

Authority

This Instrument exercises various powers in Part VII of the Act, as set out below:

Pharmaceutical benefits listed on the PBS

Subsection 85(2) provides that the Minister may declare drugs and medicinal preparations to which Part VII applies. A drug or medicinal preparation for which there is a declaration in force under subsection 85(2) is a ‘listed drug’ (subsection 84(1)). Subsections 85(3) and 85(5) respectively provide that the Minister may determine the form or forms of a listed drug and the manner of administration of a form of a listed drug. A listed drug in a determined form with a determined manner of administration for that form is a pharmaceutical item (section 84AB). Subsection 85(6) provides that the Minister may determine a brand of a pharmaceutical item.

The Minister may also determine the responsible person for a brand of a pharmaceutical item (subsection 84AF(1)). Under the provisions of section 84AK the Minister may determine the determined quantity and pack quantity for a brand of a pharmaceutical item.

Prescribing pharmaceutical benefits

Paragraph 85A(2)(a) allows the Minister to determine the maximum quantity or number of units of the pharmaceutical item in a pharmaceutical benefit (or of the pharmaceutical benefit where there is no pharmaceutical item) that may, in one prescription, be directed to be supplied on one occasion. Paragraph 85A(2)(b) also allows the Minister to determine the maximum number of occasions on which the supply of the pharmaceutical benefit may, in one prescription, be directed to be repeated. The maximum quantities and repeats may be determined for all purposes or for particular purposes.

Subsection 85(7) provides that the Minister may determine the circumstances in which a prescription may be written for the supply of a pharmaceutical benefit.

Section 88 provides that the Minister may determine the pharmaceutical benefits that may be prescribed by different classes of prescribers, including medical practitioners (subsection 88(1)), participating dental practitioners (subsection 88(1A)), authorised optometrists (subsection 88(1C)), authorised midwives (subsection 88(1D)) and authorised nurse practitioners (subsection 88(1E)).

Paragraph 88(1EB) provides that the Minister can list pharmaceutical benefits without determining any authorised prescribers for the benefit allowing the benefit to be supplied only.

This legislative instrument is made pursuant to section 88 and subsection 100(2) of the Act.

Supplying pharmaceutical benefits

Subsection 85(2A) provides that the Minister must declare that a particular listed drug can only be provided under a special arrangement under section 100 if the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended under subsection 101(4AAD) that the drug be made available only under special arrangements under section 100.

Subsection 85(2AA) provides that the Minister must declare that a particular listed drug can only be provided under one or more of the prescriber bag provisions if the PBAC has recommended under subsection 101(4AACA) that the drug be made available only under one or more of the prescriber bag provisions.

Subsection 85(6A) provides that the Minister may also determine for the purposes of paragraph 103(2A)(b) that a brand of a pharmaceutical item determined under subsection 85(6) is to be treated as equivalent to one or more other brands of pharmaceutical items.

Paragraph 85(7A) provides that the Minister may determine that a particular pharmaceutical benefit may only be supplied under one or more of the prescriber bag provisions.

Paragraph 85(8)(a) provides that the Minister may determine that a particular pharmaceutical benefit may only be supplied under special arrangements under section 100.

Paragraph 85(8)(b) provides that the Minister may determine that a particular pharmaceutical benefit may only be supplied under special arrangements under section 100 for one or more of the circumstances determined for that pharmaceutical benefit under subsection 85(7).

Variation and revocation

Unless there is an express power to revoke or vary PB 26 of 2024 cited in this Instrument and explanatory statement, subsection 33(3) of the *Acts Interpretation Act 1901* is relied upon to revoke or vary PB 26 of 2024.

Subsection 101(4AAA) allows the Minister to, by legislative instrument, revoke or vary a subsection 85(2) declaration in relation to a drug or medicinal preparation. Advice from the PBAC is required if the effect of the legislative instrument would be that a drug or medicinal preparation would cease to be a listed drug (subsection 101(4AAB)).

Changes to PB 26 of 2024 made by this Instrument

Schedule 1 to this Instrument provides for the addition to the PBS Schedule of the drugs eflornithine and foslevodopa with foscarbidopa, and forms of the listed drugs drospirenone, drospirenone with ethinylestradiol, omalizumab, and ustekinumab. It also provides for the deletion of the listed drug quinapril with hydrochlorothiazide, and forms of the listed drugs afatinib, insect allergen extract-yellow jacket venom, morphine, and tenofovir with emtricitabine, and the alteration of circumstances in which prescriptions may be written for the supply of the listed drugs abemaciclib, adalimumab, cabozantinib, durvalumab, ipilimumab, nivolumab, nivolumab with relatlimab, pembrolizumab, and ustekinumab.

Schedule 1 to this Instrument also provides for the following changes:

* the addition of 22 brands of existing pharmaceutical items
* the deletion of 20 brands of existing pharmaceutical items
* the alteration of a form for an existing pharmaceutical item
* the alteration of number of repeats for a brand of an existing pharmaceutical item
* the supply only period commencing for 3 pharmaceutical items covered under Supply Only arrangements.
* the supply only period ending for 2 pharmaceutical items covered under Supply Only arrangements.

These changes are summarised, by subject matter, in the Attachment.

Consultation

The involvement of interested parties through the membership of the PBAC constitutes a formal and ongoing process of consultation. The PBAC is an independent expert body established by section 100A of the Act which makes recommendations to the Minister about which drugs and medicinal preparations should be available to Australians as pharmaceutical benefits. The PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC. In addition, an industry nominee has been appointed to the PBAC membership under the PBS Access and Sustainability Package of reforms announced in May 2015. When recommending the listing of a medicine on the PBS, PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.

Pharmaceutical companies are consulted throughout the process of the listing of their medicines on the PBS and in relation to changes to those listings. This includes the company submission to the PBAC and involvement throughout the PBAC process, negotiations or consultation on price, guarantee of supply and agreement to final listing details.

It was considered that further consultation for this Instrument was unnecessary due to the nature of the consultation that had already taken place.

General

A provision-by-provision description of this Instrument is contained in the Attachment.

This Instrument commences on 1 August 2025.

This Instrument is a legislative instrument for the purposes of the *Legislation Act 2003.*

**ATTACHMENT**

**PROVISION-BY-PROVISION DESCRIPTION OF *NATIONAL HEALTH (LISTING OF PHARMACEUTICAL BENEFITS) AMENDMENT (AUGUST UPDATE) INSTRUMENT 2025***

**Section 1** **Name of Instrument**

This section provides that the name of the Instrument is the *National Health (Listing of Pharmaceutical Benefits) Amendment (August Update) Instrument 2025* and may also be cited as PB 84 of 2025.

**Section 2** **Commencement**

Subsection 2(1) provides for commencement dates of each of the provisions specified in Column 1 of the table, in accordance with Column 2 of the table. In accordance with Column 2 of the table, Schedule 1 to the Instrument commences on 1 August 2025.

**Section 3** **Authority**

This section specifies that sections 84AF, 84AK, 85, 85A, 88 and 101 of the *National Health Act 1953* provide the authority for the making of this Instrument.

**Section 4** **Schedules**

This section provides that each instrument that is specified in a Schedule to the Instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to the Instrument has effect according to its terms.

**Schedule 1** **Amendments**

The amendments in Schedule 1 involve the addition and deletion of drugs, the addition and deletion of forms of listed drugs, the addition and deletion of brands, the alteration of a form for an existing pharmaceutical item, the alteration of number of repeats for a brand of an existing pharmaceutical benefit, the supply only period commencing and ending for pharmaceutical items covered under Supply Only arrangements, and the alteration of circumstances for prescribing various pharmaceutical benefits available on the Pharmaceutical Benefits Scheme. These changes are summarised below.

SUMMARY OF CHANGES TO THE PHARMACEUTICAL BENEFITS SCHEME  
MADE BY SCHEDULE 1 OF THIS INSTRUMENT

Drug Addition

| **Listed Drug** |
| --- |
| Eflornithine |
| Foslevodopa with foscarbidopa |

Drug Deletion

| **Listed Drug** |
| --- |
| Quinapril with hydrochlorothiazide |

Form Addition

|  |  |
| --- | --- |
| **Listed Drug** | **Form** |
| Drospirenone | Pack containing 24 tablets 4 mg and 4 inert tablets, 3 |
| Drospirenone with ethinylestradiol | Pack containing 24 tablets 3 mg drospirenone with 20 micrograms ethinylestradiol and 4 inert tablets |
| Omalizumab | Injection 75 mg in 0.5 mL single dose pre-filled pen |
|  | Injection 150 mg in 1 mL single dose pre-filled pen |
|  | Injection 300 mg in 2 mL single dose pre-filled pen |
| Ustekinumab | Injection 45 mg in 0.5 mL single use pre-filled syringe |

Form Deletion

| **Listed Drug** | **Form** |
| --- | --- |
| Afatinib | Tablet 50 mg |
| Insect allergen extract-yellow jacket venom | Injection set containing 550 micrograms with diluent |
| Morphine | Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL (RA-Morph)(S19A) |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg (S19A) |

Brand Addition

|  |  |
| --- | --- |
| **Listed Drug** | **Form and Brand** |
| Abiraterone | Tablet containing abiraterone acetate 250 mg *(ZYRON)* |
|  | Tablet containing abiraterone acetate 500 mg *(ZYRON)* |
| Dabigatran etexilate | Capsule 75 mg (as mesilate) *(Dabigatran Viatris)* |
|  | Capsule 110 mg (as mesilate) *(Dabigatran Viatris)* |
|  | Capsule 150 mg (as mesilate) *(Dabigatran Viatris)* |
| Denosumab | Injection 60 mg in 1 mL pre-filled syringe *(Jubbonti)* |
|  | Injection 120 mg in 1.7 mL *(Wyost)* |
| Drospirenone with ethinylestradiol | Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets *(Isabelle; Rosalee; Yelena)* |
| Escitalopram | Tablet 10 mg (as oxalate) *(ESCITALOPRAM-WGR)* |
|  | Tablet 20 mg (as oxalate) *(ESCITALOPRAM-WGR)* |
| Isotretinoin | Capsule 20 mg *(Isotretinoin Dr.Reddy's)* |
| Omalizumab | Injection 75 mg in 0.5 mL single dose pre-filled syringe *(Omlyclo)* |
|  | Injection 150 mg in 1 mL single dose pre-filled syringe *(Omlyclo)* |
| Rivaroxaban | Tablet 15 mg *(Relaban)* |
|  | Tablet 20 mg *(Relaban)* |
| Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) *(Rizatriptan-Au)* |
| Ustekinumab | Injection 90 mg in 1 mL single use pre-filled syringe *(Steqeyma)* |
|  | Solution for I.V. infusion 130 mg in 26 mL *(Steqeyma)* |
| Varenicline | Box containing 11 tablets 0.5 mg and 42 tablets 1 mg *(Varenicline Lupin)* |
|  | Tablet 1 mg *(Varenicline Lupin)* |

Brand Deletion

| **Listed Drug** | **Form and Brand** |
| --- | --- |
| Aciclovir | Tablet 800 mg *(Aciclovir APOTEX)* |
| Arsenic | Injection concentrate containing arsenic trioxide 10 mg in 10 mL *(Arsenic Trioxide-AFT)* |
| Bortezomib | Powder for injection 3.5 mg *(Bortezomib Sandoz)* |
| Fentanyl | Transdermal patch 2.1 mg *(Durogesic 12)* |
|  | Transdermal patch 4.2 mg *(Durogesic 25)* |
|  | Transdermal patch 8.4 mg *(Durogesic 50)* |
|  | Transdermal patch 12.6 mg *(Durogesic 75)* |
|  | Transdermal patch 16.8 mg *(Durogesic 100)* |
| Fluorouracil | Injection 1000 mg in 20 mL *(Fluorouracil Ebewe)* |
|  | Injection 5000 mg in 100 mL *(Fluorouracil Ebewe)* |
| Granisetron | Concentrated injection 3 mg (as hydrochloride) in 3 mL *(Granisetron-AFT)* |
| Montelukast | Tablet, chewable, 4 mg (as sodium) *(Montelukast Mylan)* |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg *(Olmekar HCT 20/5/12.5)* |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg *(Olmekar HCT 40/10/12.5)* |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg *(Olmekar HCT 40/10/25)* |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg *(Olmekar HCT 40/5/12.5)* |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg *(Olmekar HCT 40/5/25)* |
| Omalizumab | Injection 150 mg in 1 mL single dose pre-filled syringe *(Xolair)* |
| Paroxetine | Tablet 20 mg (as hydrochloride) *(Noumed Paroxetine)* |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg *(Tenofovir APOTEX)* |

Form Alteration

| **Listed Drug** | **Form** |
| --- | --- |
| Hydromorphone | ***From:*** Oral solution containing hydromorphone hydrochloride 1mg per mL, 1mL (S19A) |
|  | ***To:*** Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL (S19A) |

Number of Repeats Alteration

| **Listed Drug** | **Form** | **Number of Repeats** | |
| --- | --- | --- | --- |
| Migalastat | Capsule containing 150 mg migalastat hydrochloride (equivalent to 123 mg migalastat) | ***From:*** 5 | ***To:*** 6 |

Supply Only – Period Commencing

| **Listed Drug** | **Form** |
| --- | --- |
| Amino acid formula with vitamins and minerals without lysine and low in tryptophan | Sachets containing oral powder 24 g, 30 (GA gel) |
| Betaxolol | Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL |
| Tenecteplase | Powder for injection 50 mg with solvent |

Supply Only – Period Ending

| **Listed Drug** | **Form** |
| --- | --- |
| Glycomacropeptide and essential amino acids with vitamins and minerals | Sachets containing oral powder 16 g, 60 (PKU Build 10) |
| Protein hydrolysate formula with medium chain triglycerides | Oral powder 400 g (Alfaré) |

Alteration of Circumstances in Which a Prescription May be Written

| **Listed Drug** | **Listed Drug** |
| --- | --- |
| Abemaciclib | Nivolumab |
| Adalimumab | Nivolumab with relatlimab |
| Cabozantinib | Pembrolizumab |
| Durvalumab | Ustekinumab |
| Ipilimumab |  |

Documents Incorporated by Reference

|  |  |  |
| --- | --- | --- |
| ***Listed Drug*** | ***Document Incorporated*** | ***Document access*** |
| Nivolumab with relatlimab  Ustekinumab | **Approved Product Information/Australian Product Information/TGA-approved Product Information.** The document is incorporated as in force on the day this Instrument takes effect, pursuant to paragraph 14(1)(b) of the *Legislation Act 2003*.  This document provides health professionals with a summary of the scientific information relevant to the safe and effective use of a prescription medicine. | TGA-approved Product Information is available for download for free from the TGA website: https://www.tga.gov.au/product-information-0 |
| Ustekinumab | **Crohn Disease Activity Index (CDAI).** The document is incorporated as in force on the day this Instrument takes effect, pursuant to paragraph 14(1)(b) of the *Legislation Act 2003.*  The Crohn’s Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn’s disease. | Crohn Disease Activity Index (CDAI) is available for download for free from the PubMed website: https://pubmed.ncbi.nlm.nih.gov/12786607/  A CDAI score calculation form is included in the Services Australia application form |
| Ustekinumab | **Mayo clinic score and partial Mayo clinic score.** The document is incorporated as in force on the day this Instrument takes effect, pursuant to paragraph 14(1)(b) of the *Legislation Act 2003.*  The Mayo clinic score and the partial Mayo clinic score (an abbreviated form of the Mayo clinic score) are medical diagnostic tools used to measure disease activity, in a standardised way, in Ulcerative Colitis through the evaluation of symptoms. | The Mayo clinic score and the partial Mayo clinic score are available to download for free from the Inflammatory Bowel Diseases Journal via the Oxford University Press website: https://academic.oup.com/ibdjournal /article/14/12/1660/4654949?login=true |
| Abemaciclib | **Nottingham grading system.** The document is incorporated as in force on the day this Instrument takes effect, pursuant to paragraph 14(1)(b) of the *Legislation Act 2003*.  The Nottingham grading system is the histologic grading system developed by Elston and Ellis as a modification of the Scarff-Bloom-Richardson grading system. It is used to grade breast cancer cells by describing how different a cancer cell's appearance and growth patterns are from normal, healthy breast cells. | The Notting grading system is available for download for free from the PubMed website: https://pubmed.ncbi.nlm.nih.gov/1757079/ |
| Ustekinumab | **Psoriasis Area Severity Index (PASI).** The document is incorporated as in force on the day this Instrument takes effect, pursuant to paragraph 14(1)(b) of the *Legislation Act 2003.*  The PASI is a widely used tool that enables measurement of the severity and extent of baseline and response of therapy in psoriasis. | The PASI calculation form is available for download for free from the Services Australia website: https://www.servicesaustralia.gov.au/ and forms part of the SA authority application process. |
| Durvalumab  Ipilimumab  Nivolumab  Nivolumab with relatlimab | **World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) Performance Status/Performance Status Score.** The document is incorporated as in force on the day this Instrument takes effect, pursuant to paragraph 14(1)(b) of the *Legislation Act 2003.*  The WHO/ECOG performance status is a standard medical diagnostic tool used to measure how cancer impacts a patient’s daily living abilities, by evaluating a patient’s level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). | The WHO/ECOG Performance Status is available for download for free from the ECOG-ACRIN Cancer Research Group website: https://ecog-acrin.org/resources/ecog-performance-status |

Statement of Compatibility with Human Rights

*Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011*

**National Health (Listing of Pharmaceutical Benefits) Amendment (August Update) Instrument 2025**

**(PB 84 of 2025)**

This Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

Overview of the Instrument

The *National Health (Listing of Pharmaceutical Benefits) Amendment (August Update) Instrument 2025*(the Instrument) amends the *National Health (Listing of Pharmaceutical Benefits) Instrument 2024* (PB 26 of 2024) (the Principal Instrument) which determines the pharmaceutical benefits that are listed on the Schedule of Pharmaceutical Benefits (the Schedule) through declarations of drugs and medicinal preparations, and determinations of forms, manners of administration and brands. It also provides for related matters (responsible persons, prescribing circumstances, schedule equivalence, maximum quantities, number of repeats, determined quantities, pack quantities, section 100 only status and prescriber bag only status).

Human rights implications

The Instrument engages Articles 9 and 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR), specifically the rights to social security and health.

The Right to Social Security

The right to social security is contained in Article 9 of the ICESCR. It requires that a country must, within its maximum available resources, ensure access to a social security scheme that provides a minimum essential level of benefits to all individuals and families that will enable them to acquire at least essential health care. Countries are obliged to demonstrate that every effort has been made to use all resources that are at their disposal in an effort to satisfy, as a matter of priority, this minimum obligation.

The UN Committee on Economic Social and Cultural Rights reports that there is a strong presumption that retrogressive measures taken in relation to the right to social security are prohibited under ICESCR. In this context, a retrogressive measure would be one taken without adequate justification that had the effect of reducing existing levels of social security benefits, or of denying benefits to persons or groups previously entitled to them. However, it is legitimate for a Government to re-direct its limited resources in ways that it considers to be more effective at meeting the general health needs of all society, particularly the needs of the more disadvantaged members of society.

The Right to Health

The right to the enjoyment of the highest attainable standard of physical and mental health is contained in Article 12(1) of the ICESCR. The Committee has stated that the right to health is not a right for each individual to be healthy, but is a right to a system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health.

The Committee reports that the ‘highest attainable standard of health’ takes into account the country’s available resources. This right may be understood as a right of access to a variety of public health and health care facilities, goods, services, programs, and conditions necessary for the realisation of the highest attainable standard of health.

Analysis

The Instrument advances the right to health and the right to social security by providing new drugs, forms and brands of existing listed drugs, and ensuring the deletion of drugs, forms and brands of listed drugs does not affect access to subsidised medicines. The Pharmaceutical Benefits Scheme (PBS) is a benefit scheme which assists with advancement of these human rights by providing for subsidised access by patients to medicines. The recommendatory role of the Pharmaceutical Benefits Advisory Committee (PBAC) ensures that decisions about subsidised access to medicines on the Schedule are evidence-based. The Instrument includes the addition of 2 new drugs, the addition of 6 new forms of existing drugs, and the addition of 22 new brands across 20 existing forms, which allows for greater patient access to these drugs.

When a sponsor submits a request to delist a drug from the PBS, subsection 101(4AAB) of the *National Health Act 1953* requires that the Minister or their delegate obtain advice from the Pharmaceutical Benefits Advisory Committee (PBAC), an independent and expert advisory body, before varying or revoking declarations under subsection 85(2) so as to delist the drug. In these instances, one of the matters which the PBAC provides advice on is whether the delisting of a drug will result in an unmet clinical need for patients. The PBAC also considers whether the delisting of a form of a drug will result in an unmet clinical need for patients.

Written advice from the PBAC is tabled with the monthly amendments to the Principal Instrument. An unmet clinical need would arise when a currently treated patient population would be left without treatment options once a delisting occurs. Alternative treatment options could include using a different: form, strength or drug. The PBAC considered the delisting of drugs and forms of drugs in the abovementioned instruments would not result in an unmet clinical need, except where indicated for a particular form of drug below. Where the PBAC has identified an unmet clinical need, a Supply Only period will be instituted as outlined below to allow opportunity for patients to transition to an alternative treatment option. The delisting of these items will not affect access to the drugs (or an alternative treatment if required), as affected patients will be able to access alternative medicines through the PBS, and the delisting is unlikely to have an effect on the amount patients pay for those drugs, as co-payment amounts are capped, ensuring their rights to social security are maintained. From 1 January 2024, these amounts are $31.60 for general patients and $7.70 for concession card holders.

Where there are many brands of a listed drug and form, then the delisting of one brand will not adversely affect members of the public as they will be able to obtain any of the other equivalent brands. The delisting of brands in this Instrument will not affect access to the drugs, as affected patients will be able to access equivalent brands, at the same cost. Consequently, the brand delistings in this instrument do not result in an unmet clinical need. Note that delisting of maximum quantities, number of repeats, and pack sizes are equivalent to brand delistings.

The drug afatinib in the form tablet 50 mg (Giotrif) was requested to be delisted from the PBS Schedule by the sponsor. The PBAC noted the low number of services in the last financial year and that other strengths of afatinib tablets remain available on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.

The drug amino acid formula with vitamins and minerals without lysine and low in tryptophan in the form sachets containing oral powder 24 g, 30 (GA gel) was requested to be delisted from the PBS Schedule by the sponsor. The PBAC noted the low number of services in the previous financial year and that the sponsor intends to list an alternative product on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need, provided the alternative product is listed on the PBS. This item will be available on the PBS Schedule under Supply Only arrangements for a period of a month, allowing patients with a pre-existing valid prescription to access this item pending transition to an alternative treatment.

The drug betaxolol in the form eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL (Betoptic) was requested to be delisted from the PBS Schedule by the sponsor. The PBAC noted the moderate number of services in the last financial year. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain the item on the PBS if possible. However, the sponsor decided to proceed with the delisting as the product is being discontinued due to manufacturing reasons. This item will be available on the PBS Schedule under Supply Only arrangements for a period of 3 months, allowing patients with a pre-existing valid prescription to access this item pending transition to an alternative treatment.

The drug insect allergen extract-yellow jacket venom in the form injection set containing 550 micrograms with diluent (Hymenoptera Yellow Jacket Venom) was requested to be delisted from the PBS schedule following agreement from the sponsor. The temporary approval under section 19A of the *Therapeutic Goods Act 1989* granted by the Therapeutic Goods Administration in respect of this drug for importation and supply of a medicine not on the Australian Register of Therapeutic Goods lapsed on 31 May 2025. Patient access has not been affected as the Australian Register of Therapeutic Goods approved form of the drug is now available and remains PBS subsidised and accessible for patients.

The drug morphine in the form oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL (RA-Morph)(S19A) (RA-Morph (NZ)) was requested to be delisted from the PBS schedule following agreement from the sponsor. The temporary approval under section 19A of the *Therapeutic Goods Act 1989* granted by the Therapeutic Goods Administration in respect of this drug for importation and supply of a medicine not on the Australian Register of Therapeutic Goods lapsed on 31 May 2025. Patient access has not been affected as the Australian Register of Therapeutic Goods approved form of the drug is now available and remains PBS subsidised and accessible for patients.

The drug quinapril with hydrochlorothiazide in the each of the forms tablet 10 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide (Accuretic 10/12.5mg) and tablet 20 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide (Accuretic 20/12.5mg) was requested to be delisted from the PBS Schedule by the sponsor. The PBAC noted the low number of services in the previous financial year and that there are multiple alternatives listed on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.

The drug tenecteplase in the form powder for injection 50 mg with solvent (Metalyse) was requested to be delisted from the PBS Schedule by the sponsor. The PBAC noted the low number of services in the previous financial year and emphasised the need to retain this product as there are no suitable alternatives available on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain the item on the PBS if possible. However, the sponsor decided to proceed with the delisting as the product is being discontinued due to manufacturing reasons. This item will be available on the PBS Schedule under Supply Only arrangements for a period of 3 months, allowing patients with a pre-existing valid prescription to access this item pending transition to an alternative treatment.

The drug tenofovir with emtricitabine in the form tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg (S19A) (Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/300 mg Tablets (Laurus Labs, USA)) was requested to be delisted from the PBS schedule following agreement from the sponsor. The temporary approval under section 19A of the *Therapeutic Goods Act 1989* granted by the Therapeutic Goods Administration in respect of this drug for importation and supply of a medicine not on the Australian Register of Therapeutic Goods lapsed on 31 May 2025. Patient access has not been affected as the Australian Register of Therapeutic Goods approved form of the drug is now available and remains PBS subsidised and accessible for patients.

Conclusion

This Instrument is compatible with human rights because it advances the protection of human rights.

Rebecca Richardson  
Assistant Secretary  
PBS Listing, Pricing and Policy Branch  
Technology Assessment and Access Division  
Department of Health, Disability and Ageing